Introduction
Methods
Study design and data source
Study population
Outcomes and statistical analyses
Results
Baseline characteristics
Characteristics | Number | Column N % | |
---|---|---|---|
Sex | Female | 543 | 45.14% |
Male | 660 | 54.86% | |
Age group | 0–19 years | 7 | 0.58% |
20–39 years | 55 | 4.57% | |
40–59 years | 333 | 27.68% | |
50–69 years | 709 | 58.94% | |
70 years–older | 99 | 8.23% | |
Race (White, Black, other) | White | 1124 | 93.43% |
Black | 34 | 2.83% | |
Othera | 45 | 3.74% | |
Marital status at diagnosis | Divorced | 59 | 4.90% |
Married (including common law) | 806 | 67.00% | |
Separated | 11 | 0.91% | |
Single (never married) | 110 | 9.14% | |
Unknown | 87 | 7.23% | |
Widowed | 130 | 10.81% | |
State | California | 232 | 19.29% |
Connecticut | 187 | 15.54% | |
Georgia | 71 | 5.90% | |
Hawaii | 42 | 3.49% | |
Iowa | 169 | 14.05% | |
Michigan | 185 | 15.38% | |
New Mexico | 54 | 4.49% | |
Utah | 79 | 6.57% | |
Washington | 184 | 15.30% | |
AYA site/WHO 2008b | 1.2 Acute myeloid leukemia | 3 | 0.25% |
1.3 Chronic myeloid leukemia | 4 | 0.33% | |
1.4 Other and unspecified leukemia | 19 | 1.58% | |
2.1 Non-Hodgkin lymphoma | 83 | 6.90% | |
2.2 Hodgkin lymphoma | 4 | 0.33% | |
3.1.1 Specified low-grade astrocytic tumors | 1 | 0.08% | |
3.1.3 Astrocytoma, NOS | 2 | 0.17% | |
3.2 Other glioma | 2 | 0.17% | |
4.1 Osteosarcoma | 1 | 0.08% | |
4.2 Chondrosarcoma | 3 | 0.25% | |
5.1 Fibromatous neoplasms | 1 | 0.08% | |
5.3.1.1 Specified (excluding Kaposi sarcoma) | 8 | 0.67% | |
5.3.1.2 Kaposi sarcoma | 2 | 0.17% | |
6.1 Germ cell and trophoblastic neoplasms of gonads | 9 | 0.75% | |
7.1 Melanoma | 114 | 9.48% | |
7.2 Skin carcinomas | 6 | 0.50% | |
8.1 Thyroid carcinoma | 23 | 1.91% | |
8.2.1 Nasopharyngeal carcinoma | 1 | 0.08% | |
8.2.2 Other sites in lip, oral cavity, and pharynx | 37 | 3.08% | |
8.2.3 Nasal cav, mid ear, sinus, larynx, ill-def head/neck | 19 | 1.58% | |
8.3 Carcinoma of trachea, bronchus, and lung | 39 | 3.24% | |
8.4 Carcinoma of breast | 206 | 17.12% | |
8.5.1 Carcinoma of kidney | 17 | 1.41% | |
8.5.2 Carcinoma of bladder | 65 | 5.40% | |
8.5.3 Carcinoma of gonads | 14 | 1.16% | |
8.5.4 Carcinoma of cervix and uterus | 51 | 4.24% | |
8.5.5 Carc of oth and ill-def sites, geniourinary tract | 295 | 24.52% | |
8.6.1 Carcinoma of colon and rectum | 131 | 10.89% | |
8.6.2 Carcinoma of stomach | 7 | 0.58% | |
8.6.3 Carcinoma of liver and intrahepatic bile ducts | 3 | 0.25% | |
8.6.5 Carc oth and ill-def sites, gastrointestinal tract | 7 | 0.58% | |
8.7.2 Carcinoma of other and ill-defined sites, NOS | 9 | 0.75% | |
9.2.3 Myeloma, mast cell, misc. lymphoreticular neo, NOS | 9 | 0.75% | |
9.2.4 Other specified neoplasms, NOS | 5 | 0.42% | |
10 Unspecified Malignant Neoplasms | 3 | 0.25% |
Risk of second primary eye or ocular adnexal malignancy following a cancer diagnosis
C69.0-Conjunctiva | C69.1-Cornea | C69.2-Retina | C69.3-Choroid | C69.4-Ciliary body | C69.9-Eye, NOS | |||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
NE1 | O/E2 | NE | O/E | NE | O/E | NE | O/E | NE | O/E | NE | O/E | |
Total | 148 | 1.05 | 9 | 0.80 | 6 | 0.79 | 379 | 1.04 | 93 | 1.43# | 49 | 0.98 |
Sex | ||||||||||||
Female | 50 | 1.04 | 1 | 0.50 | 5 | 1.36 | 173 | 1.08 | 41 | 1.39 | 19 | 0.85 |
Male | 98 | 1.05 | 8 | 0.86 | 1 | 0.25 | 206 | 1.02 | 52 | 1.47# | 30 | 1.09 |
Age at diagnosis of first malignancy | ||||||||||||
0–19 years | 0 | 0.00 | 0 | 0.00 | 1 | 2.78 | 0 | 0.00 | 1 | 6.77 | 0 | 0.00 |
20–39 years | 6 | 1.37 | 0 | 0.00 | 0 | 0.00 | 18 | 1.24 | 7 | 3.00# | 1 | 0.78 |
40–59 years | 38 | 1.13 | 0 | 0.00 | 1 | 0.47 | 125 | 1.09 | 28 | 1.50 | 15 | 1.25 |
60–79 years | 95 | 1.07 | 6 | 0.83 | 4 | 0.89 | 216 | 1.02 | 50 | 1.27 | 28 | 0.91 |
80+ years | 9 | 0.64 | 3 | 1.36 | 0 | 0.00 | 20 | 0.92 | 7 | 1.68 | 5 | 0.86 |
Site recode ICD-O-3/WHO 2008 of first malignancy | ||||||||||||
All solid tumors | 125 | 0.95 | 7 | 0.66 | 6 | 0.86 | 358 | 1.06 | 84 | 1.40# | 42 | 0.91 |
Oral cavity and pharynx | 8 | 2.30 | 0 | 0.00 | 0 | 0.00 | 8 | 0.88 | 2 | 1.17 | 2 | 1.63 |
Digestive system | 17 | 0.81 | 2 | 1.04 | 0 | 0.00 | 48 | 0.96 | 15 | 1.57 | 8 | 1.02 |
Respiratory system | 10 | 1.37 | 1 | 1.62 | 0 | 0.00 | 11 | 0.58 | 7 | 1.93 | 4 | 1.52 |
Bones and joints | 0 | 0.00 | 0 | 0.00 | 1 | 79.34# | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 |
Soft tissue including heart | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 | 2 | 1.02 | 1 | 2.89 | 0 | 0.00 |
Skin excluding basal and squamous | 12 | 1.58 | 2 | 3.79 | 0 | 0.00 | 36 | 1.64# | 4 | 1.12 | 1 | 0.40 |
Melanoma of the skin | 11 | 1.56 | 1 | 2.06 | 0 | 0.00 | 35 | 1.71# | 4 | 1.19 | 1 | 0.43 |
Other non-epithelial skin | 1 | 1.80 | 1 | 23.66 | 0 | 0.00 | 1 | 0.71 | 0 | 0.00 | 0 | 0.00 |
Breast | 16 | 0.77 | 0 | 0.00 | 2 | 1.33 | 86 | 1.23 | 15 | 1.20 | 7 | 0.74 |
Female genital system | 3 | 0.36 | 0 | 0.00 | 2 | 3.05 | 22 | 0.77 | 8 | 1.48 | 3 | 0.75 |
Male genital system | 46 | 1.01 | 3 | 0.67 | 1 | 0.57 | 108 | 1.14 | 19 | 1.19 | 15 | 1.15 |
Prostate | 44 | 0.99 | 3 | 0.68 | 1 | 0.58 | 103 | 1.13 | 19 | 1.23 | 15 | 1.18 |
Urinary system | 9 | 0.65 | 0 | 0.00 | 0 | 0.00 | 26 | 0.80 | 10 | 1.69 | 2 | 0.44 |
Brain and other nervous system | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 | 2 | 8.04 | 0 | 0.00 |
Endocrine system | 4 | 1.58 | 0 | 0.00 | 0 | 0.00 | 12 | 1.50 | 1 | 0.76 | 0 | 0.00 |
Thyroid | 4 | 1.65 | 0 | 0.00 | 0 | 0.00 | 11 | 1.43 | 1 | 0.79 | 0 | 0.00 |
All lymphatic and hematopoietic diseases | 19 | 2.17# | 1 | 1.54 | 0 | 0.00 | 19 | 0.80 | 9 | 2.15 | 5 | 1.64 |
Lymphoma | 15 | 2.84# | 1 | 2.74 | 0 | 0.00 | 8 | 0.55 | 8 | 3.16# | 4 | 2.22 |
Hodgkin lymphoma | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 | 1 | 4.64 |
Non-Hodgkin lymphoma | 15 | 3.26# | 1 | 3.06 | 0 | 0.00 | 8 | 0.64 | 8 | 3.69# | 3 | 1.89 |
Myeloma | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 | 2 | 0.90 | 0 | 0.00 | 0 | 0.00 |
Leukemia | 4 | 1.53 | 0 | 0.00 | 0 | 0.00 | 9 | 1.32 | 1 | 0.81 | 1 | 1.07 |
Lymphocytic leukemia | 2 | 0.95 | 0 | 0.00 | 0 | 0.00 | 8 | 1.49 | 1 | 1.02 | 0 | 0.00 |
Non-lymphocytic leukemia | 2 | 3.94 | 0 | 0.00 | 0 | 0.00 | 1 | 0.69 | 0 | 0.00 | 1 | 5.54 |
Acute non-lymphocytic leukemia | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 | 1 | 1.68 | 0 | 0.00 | 0 | 0.00 |
Myeloid and monocytic leukemia | 2 | 4.47 | 0 | 0.00 | 0 | 0.00 | 1 | 0.78 | 0 | 0.00 | 1 | 6.35 |
Kaposi sarcoma | 1 | 5.54 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 |
Miscellaneous | 3 | 4.41 | 0 | 0.00 | 0 | 0.00 | 1 | 0.55 | 0 | 0.00 | 2 | 7.59 |
C44.1-Eyelid | C69.5-Lacrimal gland | C69.6-Orbit, NOS | C69.8-Overlapping lesion of eye and adnexa | C72.3-Optic nerve | ||||||
---|---|---|---|---|---|---|---|---|---|---|
NE1 | O/E2 | NE | O/E | NE | O/E | NE | O/E | NE | O/E | |
Total | 280 | 1.35# | 50 | 1.21 | 181 | 1.15 | 21 | 1.37 | 15 | 3.82# |
Sex | ||||||||||
Female | 134 | 1.37# | 24 | 1.11 | 87 | 1.13 | 10 | 1.58 | 10 | 6.05# |
Male | 146 | 1.34# | 26 | 1.31 | 94 | 1.16 | 11 | 1.22 | 5 | 2.20 |
Age at diagnosis of second primary | ||||||||||
0–19 years | 1 | 5.78 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 | 4 | 11.51# |
20–39 years | 12 | 2.99# | 3 | 1.86 | 6 | 1.78 | 0 | 0.00 | 4 | 7.47# |
40–59 years | 60 | 1.39# | 18 | 1.38 | 45 | 1.24 | 5 | 1.45 | 3 | 2.02 |
60–79 years | 171 | 1.29# | 23 | 0.98 | 117 | 1.19 | 15 | 1.54 | 3 | 2.31 |
80+ years | 36 | 1.35 | 6 | 1.93 | 13 | 0.66 | 1 | 0.57 | 1 | 3.77 |
Site recode ICD-O-3/WHO 2008 of first malignancy | ||||||||||
All solid tumors | 251 | 1.30# | 36 | 0.94 | 148 | 1.01 | 19 | 1.33 | 13 | 3.75# |
Oral cavity and pharynx | 12 | 2.71# | 2 | 2.13 | 5 | 1.46 | 1 | 2.59 | 0 | 0.00 |
Digestive system | 32 | 1.00 | 5 | 0.85 | 23 | 0.94 | 2 | 0.83 | 1 | 2.19 |
Respiratory system | 12 | 1.22 | 3 | 1.47 | 12 | 1.59 | 1 | 1.17 | 0 | 0.00 |
Bones and joints | 1 | 4.75 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 |
Soft tissue including heart | 2 | 1.99 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 | 2 | 38.49# |
Skin excluding basal and squamous | 53 | 5.17# | 0 | 0.00 | 11 | 1.42 | 2 | 2.69 | 1 | 3.41 |
Melanoma of the skin | 51 | 5.39# | 0 | 0.00 | 9 | 1.26 | 2 | 2.90 | 1 | 3.66 |
Other non-epithelial skin | 2 | 2.55 | 0 | 0.00 | 2 | 3.34 | 0 | 0.00 | 0 | 0.00 |
Breast | 47 | 1.12 | 8 | 0.85 | 27 | 0.82 | 6 | 2.23 | 2 | 3.35 |
Female genital system | 17 | 1.02 | 1 | 0.27 | 11 | 0.84 | 1 | 0.87 | 0 | 0.00 |
Male genital system | 49 | 0.90 | 12 | 1.24 | 44 | 1.10 | 6 | 1.41 | 3 | 3.10 |
Prostate | 46 | 0.86 | 11 | 1.17 | 42 | 1.07 | 6 | 1.45 | 3 | 3.40 |
Urinary system | 24 | 1.30 | 4 | 1.20 | 14 | 1.02 | 0 | 0.00 | 0 | 0.00 |
Brain and other nervous system | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 | 3 | 33.96# |
Endocrine system | 4 | 1.17 | 1 | 1.03 | 2 | 0.72 | 0 | 0.00 | 1 | 5.69 |
Thyroid | 4 | 1.22 | 1 | 1.07 | 2 | 0.75 | 0 | 0.00 | 1 | 6.49 |
All Lymphatic and hematopoietic diseases | 22 | 1.80# | 14 | 5.41# | 29 | 3.08# | 2 | 2.18 | 2 | 4.73 |
Lymphoma | 18 | 2.44# | 12 | 7.48# | 22 | 3.87# | 0 | 0.00 | 1 | 4.50 |
Hodgkin lymphoma | 0 | 0.00 | 2 | 9.08# | 1 | 1.70 | 0 | 0.00 | 0 | 0.00 |
Non-Hodgkin lymphoma | 18 | 2.71# | 10 | 7.23# | 21 | 4.12# | 0 | 0.00 | 1 | 6.57 |
Myeloma | 0 | 0.00 | 0 | 0.00 | 4 | 4.25# | 0 | 0.00 | 0 | 0.00 |
Leukemia | 4 | 1.10 | 2 | 2.80 | 3 | 1.08 | 2 | 7.10 | 1 | 5.61 |
Lymphocytic leukemia | 2 | 0.67 | 2 | 3.59 | 2 | 0.89 | 2 | 8.73# | 0 | 0.00 |
Non-lymphocytic leukemia | 2 | 3.03 | 0 | 0.00 | 1 | 1.91 | 0 | 0.00 | 1 | 26.54 |
Acute non-lymphocytic leukemia | 2 | 8.30# | 0 | 0.00 | 1 | 5.01 | 0 | 0.00 | 0 | 0.00 |
Myeloid and monocytic leukemia | 2 | 3.48 | 0 | 0.00 | 1 | 2.19 | 0 | 0.00 | 1 | 29.46 |
Kaposi sarcoma | 0 | 0.00 | 0 | 0.00 | 1 | 6.26 | 0 | 0.00 | 0 | 0.00 |
Miscellaneous | 5 | 5.14# | 0 | 0.00 | 2 | 2.66 | 0 | 0.00 | 0 | 0.00 |